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ABSTRACT
Objective: Varicella vaccination was introduced at the
end of 1999 into the Uruguayan immunisation schedule
for children aged 12 months. Varilrix (Oka strain;
GlaxoSmithKline Biologicals) has been the only vaccine
used since then and coverage has been estimated to
exceed 90% since the start of the universal varicella
vaccination programme. We assessed the impact of the
Uruguayan varicella vaccination programme during 2005,
6 years after its introduction.
Methods: Information on hospitalisations was collected
from the main paediatric referral hospital and information
on medical consultations for varicella was collected from
two private health insurance systems in Montevideo. The
proportion of hospitalisations due to varicella and the
proportion of ambulatory visits for varicella since the
introduction of the vaccine were compared between 1999
and 2005 and 1997 and 1999 in the following age groups:
,1 year, 1–4 years, 5–9 years and 10–14 years.
Results: By 2005, the proportion of hospitalisations due
to varicella among children, was reduced by 81% overall
and by 63%, 94%, 73% and 62% in the ,1, 1–4, 5–9 and
10–14 years age groups, respectively. The incidence of
ambulatory visits for varicella among children was
reduced by 87% overall and by 80%, 97%, 81% and 65%
in the ,1, 1–4, 5–9 and 10–14 years age groups,
respectively.
Conclusions: The burden of varicella has decreased
substantially in Uruguayan children since the introduction
of the varicella vaccination, including those groups outside
the recommended vaccination age. It is expected to
decrease further as more cohorts of children are
vaccinated and herd immunity increases.
Although varicella is usually considered a mild
childhood disease, it carries a considerable public
health burden as it affects nearly all children before
the age of 10 and is not devoid of complications.
Before implementation of routine varicella vaccina-
tion in the USA, varicella caused an estimated
11 000 hospitalisations and 100 deaths every year
(or approximately 2.6 deaths per 100 000 cases), of
which approximately 43 deaths occurred in mostly
healthy children ,15 years of age.
12
Numerous clinical trials have shown that var-
icella vaccines derived from the Oka strain, isolated
in Japan in the early 70s, are safe, immunogenic
and protective against varicella in healthy children
and adults.
34These results have been confirmed by
post-licensure surveillance studies in the USA
5–7
and Israel.
8
The two most widely used varicella vaccines are
Varivax from Merck & Co. and Varilrix from
GlaxoSmithKline Biologicals. In 1995, the USA
became the first country to include varicella into
the routine immunisation calendar using a frozen
vaccine formulation (Varivax). From 1995 to 2000,
varicella cases in the USA declined by 71% to 84%,
depending on the region, with the largest decrease
observed in children aged 1–4 years. Despite
irregular acceptance and overall vaccination cover-
age below 75%, 10 years of routine immunisation
reduced varicella-related deaths from approxi-
mately 100, to 26 per year, with the highest
reduction (92%) also observed in children aged 1–4
years.
9 Hospitalisations similarly declined from a
range of 2.7–4.2 per 100 000 population from 1995
to 1998, to 0.6 and 1.5 per 100 000 population in
1999 and 2000, respectively.
10 Routine varicella
vaccination of young children is now also recom-
mended in Canada (Varilrix and Varivax),
11
Germany (Varilrix and Varivax),
12 Australia
What is already known on this topic
c Although safe and effective vaccines against
varicella disease exist, universal mass
vaccination against varicella (UMVV) is currently
undertaken by very few countries.
c Vaccine effectiveness in preventing disease and
death has been established by data from the
USA where UMVV has been underway for a
decade using a vaccine from a single
manufacturer.
c Outside the USA there is a paucity of population
effectiveness data in UMVV settings.
What this study adds
c This study provides vaccine effectiveness data
following 6 years of UMVV in Uruguay, with
more than 90% coverage since the start of the
programme.
c The data specifically describe the effect of
UMVV on hospitalisations and outpatient health
service utilisation. The findings complement and
add to those already published by US
investigators.
c The vaccine administered in Uruguay is made by
a different manufacturer to the US product and
provides additional evidence that supports the
effectiveness of Oka-strain vaccines in
preventing disease and hospitalisations due to
varicella.
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13 Qatar (Varilrix),
14 Taiwan (Varivax)
15
and South Korea (Varilrix and Varivax),
16 and is under
consideration in other European countries.
17
Among developing middle-income countries, Uruguay is
characterised by a modern and efficacious immunisation policy.
At the end of 1999, universal vaccination against varicella was
introduced among children 12 months of age.
18 No catch-up
vaccination took place. The varicella vaccine used in Uruguay,
Varilrix is, like the US-licensed vaccine Varivax, derived from the
Oka strain. Varilrix differs from the US formulation of Varivax
in its temperature stability, whereby Varilrix does not need to
be stored in the freezer.
4
Vaccines that are part of the national recommended
immunisation schedule in Uruguay are offered free of charge.
Varilrix is administered concomitantly with the measles,
mumps and rubella (MMR) vaccine, and vaccination is
mandatory before kindergarten and school entry. According to
the Uruguayan Ministry of Public Health this has resulted in a
varicella vaccination coverage of 96%, 96%, 93%, 96%, 94% and
88%, respectively, for children born in 1999, 2000, 2001, 2002,
2003 and 2004,
19 with similar coverage continuing during 2005 (J
Quian, personal communication, 2006). The aim of this study
was to assess the impact of the varicella universal vaccination
programme in Uruguay on health service utilisation for varicella
in children, 6 years after the start of the programme.
MATERIALS AND METHODS
We conducted a study of utilisation of health services for
varicella infection in the 3 years before and 6 years after
introduction of varicella vaccination (January 1997–December
2005). Data collection was retrospective between 1997 and 2003
and prospective from 2004.
Vaccine
One dose of Varilrix (0.5 ml) contains 10
3.3 plaque forming units
of live attenuated varicella-zoster (Oka strain) virus, propagated
in MRC5 human diploid cells. Varilrix is stored by refrigeration
at +2uCt o+8uC and is not affected by freezing (refrigeration-
stable formulation registered in 1994).
Study population
The study was conducted in Montevideo, the capital of
Uruguay. According to the latest census in 1996, Montevideo
has a total population of 1 344 839 among whom 294 831 are
,15 years old with the following age distribution: 20 081 aged
less than 1 year (representing 1.5% of the total population);
77 398 aged between 1 and 4 years (5.8%); 100 028 aged
between 5 and 9 years (7.4%); and 97 324 aged between 10 and
14 years (7.2%).
20
Health surveillance systems
Both public and private health surveillance systems are in place
in Uruguay. We obtained data from both systems. The public
system serves a population that is generally more disadvan-
taged, relying on the Ministry of Public Health for healthcare.
The main paediatric referral centre in this sector is the Centro
Hospitalario Pereira Rossell (CHPR). This is the only paediatric
referral hospital in Uruguay and admits cases of varying
severity, including children with complex and severe illness.
Data on hospitalisations related to varicella were obtained from
the ward registers and automated database of this hospital. All
cases were recorded, regardless of whether or not varicella was
the presenting condition.
The private health system consists of several organisations
that service a substantial proportion of the population (25% of
children ,15 years in the city of Montevideo). These organisa-
tions provide ambulatory medical services (home care, con-
sultations at polyclinics and hospital transfer in case of
emergency). Two private insurance organisations were involved
in the present study: Servicio de Urgencia Asistencia y Traslado
(SUAT) and Servicio de Emergencia Medico Movil (SEMM),
respectively, serving an average of 63 000 and 19 000 children
aged ,15 years (approximately 10% of Uruguayan children in
total). At SEMM, data were only available from 1998 onwards.
Data on ambulatory visits for varicella were extracted from
hand-written registers for the period before 1999 and from
automated databases from 1999 onwards.
Age, gender and place of residence were collected for all
reported varicella cases in the three institutions. For hospitalised
cases the following data were also obtained: diagnosis at the
time of admission, number of hospitalisation days, varicella
immunisations, admission or not in the Intensive Care Unit
(ICU), and final diagnosis and outcome for the patient.
Statistical analysis
The CHPR does not cover a well-defined population and it was
not possible to calculate or compare varicella hospitalisation
rates. Instead, the proportion of admissions for varicella
compared to the overall number of admissions was calculated.
For ambulatory visits, incidence rates could be calculated and
compared over time since membership of the private insurance
systems providing the ambulatory varicella numbers was
exactly known.
Surveillance data from the Ministry of Health show varicella
notifications prior to the introduction of routine varicella
vaccination (fig 1). Surveillance was similar for all years except
for 1985, where no data were available because the programme
was new and recently implemented. To estimate the burden of
varicella disease in the pre-vaccination period, we calculated the
proportions and incidence rates for the entire period 1997–1999
to compensate for these cycles. As data were unavailable for
1997 at SEMM we used the 1998–1999 average in this system.
Fisher exact tests were used to test the decrease between the
rates before and since the varicella vaccination programme.
Statistical analyses used SAS V8.2 (SAS institute, Cary, North
Carolina).
RESULTS
Hospitalisations
The total number of hospitalisations in the CHPR increased
from 8130 in 1997 to 15 265 in 2005. The number of varicella-
related hospitalisations varied from a maximum of 101 in 1998
to a minimum of 28 in 2005. The mean duration of varicella-
related hospitalisation was 4 days in 1997–1999 and 3, 4, 5, 3.5,
4.8 and 3.8 days in 2000, 2001, 2002, 2003, 2004 and 2005,
respectively.
The proportion of hospitalisations due to varicella, reduced by
81% overall (p,0.001) and by 63% (p,0.001), 94% (p,0.001),
73% (p,0.001) and 62% (p=0.044) by 2005 in the ,1, 1–4, 5–9
and 10–14 years age groups, respectively, compared to the
preceding years from 1997 to 1999 (table 1).
The majority of varicella cases had no underlying condition
(table 1). There was no change in the proportion of hospitalised
cases with underlying conditions over time. When present,
immunosuppression and malnourishment were the most
common preceding conditions. Since the start of the varicella
Original article
846 Arch Dis Child 2008;93:845–850. doi:10.1136/adc.2007.126243vaccination campaign in 1999, only six hospitalisations took
place in vaccinated children; in 2002, a child with nephrotic
syndrome who presented 7 days after vaccination; in 2003, a
child with skin super-infection; in 2004, a 4-year-old with
cellulitis who had been vaccinated 2 years previously; in 2005, a
2K-year-old child receiving treatment for rhabdomyosarcoma
who was vaccinated at 12 months of age; a child with febrile
seizures aged 2 years and 5 months who was vaccinated
Figure 1 Yearly number of varicella cases reported to the Uruguayan MOH, 1983–1999 (Ministerio de Salud Pu ´blica, Departamento de Vigilancia
Epidemiolo ´gica). (1985: no data). MOH, Ministry of Health.
Table 1 All and varicella-related hospitalisations in the Centro Hospitalario Pereira Rossell (CHPR), Uruguay, between 1997 and 2005
Age (years) 1997 1998 1999 2000 2001 2002 2003 2004 2005
% Reduction
(p value*)
,1
Total (N) 3081 2904 2779 3238 3901 3676 3664 4073 4094 63% (p,0.001)
Varicella (n) 8 33 28 23 16 17 14 21 12
Proportion (%) 0.26 1.14 1.01 0.71 0.41 0.46 0.38 0.52 0.29
1–4
Total (N) 2760 2709 2761 3439 4940 4676 3980 4645 4448 94% (p,0.001)
Varicella (n) 28 48 44 10 9 11 7 3 4
Proportion (%) 1.01 1.77 1.59 0.29 0.18 0.24 0.18 0.06 0.09
5–9
Total (N) 1224 1308 1468 1933 2818 2935 2999 3477 3432 73% (p,0.001)
Varicella (n) 11 11 13 5 5 13 10 11 8
Proportion (%) 0.90 0.84 0.89 0.26 0.18 0.44 0.33 0.32 0.23
10–14
Total (N) 1014 1085 1267 2325 3513 3510 2580 3136 3144 62% (p=0.044)
Varicella (n) 1 9 4 4 2 4 4 7 5
Proportion (%) 0.10 0.83 0.32 0.17 0.06 0.11 0.16 0.22 0.16
Unknown age{ 51 14 43 212 434 475 0 313 147
Total
Total (N) 8130 8020 8318 11 147 15 606 15 272 13 223 15 644 15 265 81% (p,0.001)
Varicella (n) 48 101 89 42 32 45 35 42 28
Proportion (%) 0.59 1.26 1.07 0.38 0.21 0.29 0.26 0.27 0.18
Characteristics of cases
Male/female (n) 26/22 47/54 46/43 23/19 22/10 22/23 21/14 22/20 11/17
Without underlying condition 42 88 80 40 29 41 33 34 26
Immunosuppressed/
malnourished{
3 8822407 2
Other 0 0 0 0 1 0 1 1 0
Unknown 3 5 1 0 0 0 1
Other, celiac disease, nephritic syndrome or diabetes.
*Fisher exact test, % reduction from 1997 to 1999 until 2005.
{There were no varicella cases in individuals of unknown age.
{Immunosuppression due to leukaemia, disease requiring corticosteroid therapy or HIV.
N, total number of hospitalisations; n, number of varicella-related hospitalisations.
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pneumonia who had been vaccinated at 3 years of age.
Outpatient consultations
The combined membership ,15 years of age for SUAT and
SEMM decreased from approximately 85 000 in 1998 to 65 000
in 2005. In the period 1997–1999, the incidence of medical visits
for varicella per 1000 members in the two systems was 38.8
overall and 16.2, 64.8, 44.9 and 13.9 for the ,1, 1–4, 5–9 and
10–14 years age groups, respectively. In 2005, these incidence
rates were reduced by 87% overall (p,0.001) and by 80%
(p,0.001), 97% (p,0.001), 81% (p,0.001), and 65% (p,0.001)
for the same respective age groups (table 2).
The evolution of the incidence of varicella in each system is
illustrated in fig 2.
There were 358 varicella cases treated as outpatients among
the three service providers during 2005, who were in the target
age group (.1 year of age) and for whom clinical information,
including vaccination status was available (tables 1 and 2). Of
these, 118 had been previously vaccinated. Clinical varicella
differed significantly in previously vaccinated and unvaccinated
individuals: 78.0% of vaccinated subjects had (50 lesions and
none had .150 lesions compared with 32.9% and 23.8% of
unvaccinated children, respectively (p,0.001). Fever was pre-
sent in 39.8% of vaccinated subjected versus 77.1% of
unvaccinated subjects (p,0.001) and was .38.5uC in 31.9%
and 48.6% vaccinated and unvaccinated children, respectively
(p=0.003). Complications occurred in 6.8% of vaccinated
children (cutaneous super-infection and vesicular haemorrhage)
compared with 11.7% of unvaccinated children (cutaneous
super-infection, bacterial super-infection, sepsis, scarlet fever
and cervical adenopathy) (p.0.05). Hospitalisation occurred in
0.0% and 1.2% of vaccinated and unvaccinated children,
respectively (p.0.05).
DISCUSSION
The results of this retrospective study demonstrate significant
reductions in the proportion of varicella hospitalisations in a
large public paediatric hospital (up to 86% in the age group
eligible for vaccination) compared to the pre-vaccination years
1997–1999. Furthermore, a substantial decrease was also
observed in the ambulatory cases seen at two ambulatory
healthcare providers (up to 88% in the age group eligible for
vaccination). Clinical varicella, when it occurred in vaccinated
subjects, was associated with significantly fewer and less severe
symptoms and complications than disease in unvaccinated
children.
The observed decrease in varicella incidence is neither linear,
nor constant. The initial sharp decline in 1999 is likely to be due
to cyclical increase and decrease of varicella rather than the
vaccination campaign.
21 However, the persistence of this
decrease can be attributed to vaccination and it seems justified
to assert that sustained reductions in case numbers and
hospitalisations observed in the years following the onset of
vaccination represent the true impact of the varicella vaccina-
tion programme. Without the varicella vaccination campaign,
one would likely have seen another cyclical peak and a new
increase after 2000. This is supported by data from Buenos
Aires, an adjacent province in Argentina which has no varicella
mass vaccination, where a doubling of cases was reported from
2001 to 2002.
22 The slight increase in hospitalisations in 2002 and
Table 2 Number and distribution of varicella cases in children aged ,15 years in Uruguayan private healthcare providers between 1997 and 2005
Age (years)
Servicio de Urgencia Asistencia y Traslado (SUAT) Servicio de Emergencia Medico Movil (SEMM)
1997 1998 1999 2000 2001 2002 2003 2004 2005 1998 1999 2000 2001 2002 2003 2004 2005
,1
Cases 63 86 52 22 31 14 11 7 6 106 39 46 35 17 6 16 10
Members 911 994 1064 1317 1245 2181 5446 3336 2396 8743 9604 8835 4409 3414 3223 2475 2513
Cases/1000 69.2 86.5 48.9 16.7 24.9 6.4 2.0 2.1 2.5 12.1 4.1 5.2 7.9 5.0 1.9 6.5 4.0
1–4
Cases 723 890 454 217 166 89 44 9 18 1038 369 271 165 44 23 42 26
Members 3796 4227 4787 5191 5633 7202 7106 7809 7966 20 114 20 659 19 243 17 517 14 133 13 869 9963 11 483
Cases/1000 190.5 210.6 94.8 41.8 29.5 12.4 6.2 1.2 2.3 51.6 17.9 14.1 9.4 3.1 1.7 4.2 2.3
5–9
Cases 592 709 379 245 299 248 188 79 43 769 300 248 267 138 137 187 123
Members 4148 4698 5238 5690 6218 7660 8491 7556 5950 23 383 23 826 22 490 20 725 16 913 16 715 11 854 13 894
Cases/1000 142.7 150.9 72.4 43.1 48.1 32.4 22.1 10.5 7.2 32.9 12.6 11.0 12.9 8.2 8.2 15.8 8.9
10–14
Cases 131 182 99 83 87 73 54 37 30 211 102 74 79 35 53 78 72
Members 3607 4074 4710 5190 5599 6840 7512 6430 7671 18 992 20 608 20 334 19 696 16 440 13 069 13 262 13 173
Cases/1000 36.3 44.7 21.0 16.0 15.5 10.7 7.2 5.8 3.9 11.1 4.9 3.6 4.0 2.1 4.1 5.9 5.5
Total
Cases 1509 1867 984 567 583 424 297 132 97 2124 810 639 546 234 219 323 231
Members 12 462 13 993 15 799 17 388 18 695 23 883 28 555 25 131 23 983 71 232 74 697 70 902 62 347 50 900 46 876 37 554 41 064
Cases/1000 121.1 133.4 62.3 32.6 31.2 17.8 10.4 5.3 4.0 29.8 10.8 9.0 8.8 4.6 4.7 8.6 5.6
Figure 2 Incidence of varicella in children aged ,15 years, Uruguay
1997–2005. SEMM, Servicio de Emergencia Medico Movil; SUAT,
Servicio de Urgencia Asistencia y Traslado.
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also been a result of the deteriorating economic climate in
Uruguay that led to more hospitalisations for social reasons.
We observed a fourfold difference in the incidence rates
between the two ambulatory healthcare providers. We do not
have a clear explanation for this. We can only speculate that the
thresholds for utilising the medical services seem to differ.
However, as the trends are almost identical between the two
systems (fig 2), we believe that the potential under-reporting in
one system does not invalidate our findings.
Besides the substantial reduction in incidence in the 1–4-year-
old group that were eligible for vaccination, large decreases were
alsoobservedinthe otheragegroups. Weinterpret these decreases
as indications of herd immunity already measurable in Uruguay.
In the infant group, the reduction obtained by herd immunity
was nearly as significant as the reduction observed in the
vaccinated group. Similar observations were made in the USA.
9
Uruguay has a relatively mild climate with average yearly
temperatures of 12uC–25uC. Its varicella epidemiology should be
expected to be similar to countries with mild climates in the
Northern hemisphere, including parts of the USA. Our estimates
of the incidence in the pre-vaccine period as well as the
proportional reduction achieved by universal mass vaccination
against varicella (UMVV) were comparable to those estimated in
the USA, where Merck’s Varivax vaccine is the only vaccine in
use.
10Table 3 summarises varicella epidemiologyof both countries
before and 5 to 6 years after introduction of UMVV.
The economic crisis of 2001 had a clear impact on Uruguayan
health services. We noted an increase in hospitalisations in the
public hospital and a decrease in the membership of one of the
two private healthcare services. In order to assess the potential
impact of this situation on measured incidence rates, we
calculated the average number of consultations per member of
the ambulatory systems (SEMM and SUAT). This average did
not decline during the study period (1.7 in 1998–1999 and 2.4 in
2002 when the combined membership was lowest), suggesting
that the decline observed for varicella was not due to a reduced
utilisation of the services.
Our study has some limitations. By its retrospective nature
we could not confirm reported varicella cases by laboratory
testing. It is possible that varicella cases occurring in the current
high-coverage setting are milder than before, particularly among
vaccinees, and are therefore more easily missed. This would
have caused us to overestimate the impact of the varicella
vaccination programme on the absolute number of varicella
cases. We could not estimate hospitalisation incidence rates as
the population that makes use of the CHPR is not well defined
and is expected to vary with changing economic conditions. We
believe that an economic factor, namely the severe economic
crisis in Uruguay during 2001–2002, explains the increase in
overall hospitalisations at this public hospital. This is supported
by the decrease in overall hospitalisations in 2003, in parallel
with slightly improving economic conditions and an increase in
following years that also paralleled a fall in economic condi-
tions. Public outpatient varicella attendances were not available
and it is possible that outpatient attendance and hospitalisation
rates may have differed within the public and private healthcare
sectors. Finally, varicella vaccination started in 1999, thus we
have not had opportunity to observe varicella breakthrough
cases that may potentially occur many years after vaccination.
Two theoretical concerns have hindered the widespread
acceptance of varicella vaccination beyond a handful of
countries. The first concern is that vaccination against varicella
might increase the overall morbidity related to the disease, due
to an upward shift in the average age of infection from
childhood to adulthood where risk of complication is greater.
23 24
Data from adolescents and young adults over a longer period of
observation are required to confirm this observation. The
second concern is that UMVV might increase the incidence of
herpes zoster in older age groups, as it has been suggested that
repeated exposure to varicella and the resulting natural boosting
of immunity to the latent virus could reduce the risk of its
reactivation.
25 26 We intend to test the hypothesised temporary
increase of zoster by expanding the surveillance in Uruguay to
include herpes zoster in children as well as adults, which began
in 2004. In 2006 the USA adopted a two-dose varicella
vaccination strategy, introducing a second varicella dose at
4–6 years of age with the specific aim of minimising primary
vaccine failures and reducing the incidence of breakthrough
disease.
27 This strategy is also likely to inhibit potential upward
age shifts in disease incidence and may have a positive impact
on the incidence of zoster in later life.
This study assessed the impact of Varilrix when used under
routine circumstances in a public health programme. We have
shown that universal mass vaccination against varicella in
Uruguay has highly beneficial effect in Uruguay by reducing
both hospitalisations (by 81% overall) and outpatient visits (by
87% in children ,15 years) for this disease. This beneficial effect
is expected to increase further as more cohorts of children are
vaccinated and herd protection increases. Unlike the USA,
where varicella vaccination coverage has increased rather
progressively, Uruguay serves as an example of the public
health impact of universal varicella vaccination when the
uptake is high from the very start of the programme.
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Child Healthcare Information and Learning Discussion Group (CHILD2015)
Most healthcare providers in the developing world continue to work without basic learning and
reference materials. As a result, countless numbers of children are dying for lack of knowledge.
CHILD2015 is a global email forum that explores ways to address this vital and neglected issue. Our
goal is closely linked with the UN Millennium Development Goals: By 2015, every child worldwide will
have access to an informed healthcare provider.
CHILD2015 has more than 800 members from over 90 countries. These include many leading figures in
international child health, as well as frontline health workers, researchers, librarians and producers of
health learning materials. As a member, you will have opportunities to learn from others and share your
ideas, experience and expertise.
Join today!
Membership is free of charge. To join, just send an email to admin@dgroups.org. Please include your
name, position and a brief description of your professional interests. For further details, and to view the
email archive, please see www.dgroups.org/groups/CHILD2015/ or contact the lead moderator:
neil.pakenham-walsh@ghi-net.org.
CHILD2015 is managed and moderated by the Global Healthcare Information Network and the
International Child Health Group of the Royal College of Paediatrics and Child Health, UK. CHILD2015 is
supported in kind by several leading journals, including Archives of Disease in Childhood.
CHILD2015 is also a key component of a broader global campaign, Healthcare Information For All by
2015 (www.hifa2015.org), supported by 20 leading health and development organisations including the
British Medical Association, Royal College of Nursing, and Royal College of Midwives.
‘‘CHILD2015 is an excellent forum... The contributions from developing countries are particularly
strong.’’ Dr Hugh Reyburn, Paediatrician, Kilimanjaro Christian Medical Centre, Tanzania.
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